During his address to Congress on March 4, Donald Trump alleged that the Biden administration had spent $8 million "for ...
3hon MSN
Researchers from the HIV Prevention Trials Network (HPTN) have presented results from the HPTN 094 ("INTEGRA") study at the ...
A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV prevention drug lenacapavir allows it to persist in the body for up to a year.
ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early ...
Offering mailed self-testing for HIV encouraged patients to test themselves for HIV but require methods of improving ...
ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early ...
The Conference on Retroviruses and Opportunistic Infections 2025 opened with a session dedicated to informing attendees about ...
Immunocore’s big swing for a functional HIV cure has cleared its first hurdle. | Immunocore’s big swing for a functional HIV ...
Incident HCV infection more than doubled among HIV-positive MSM with no history of injection drug use between 1995 and 2023.
Patients who struggle to take daily HIV pills can benefit from long-acting injectable treatments, a new study by researchers ...
Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...
During the opening day of the Conference on Retroviruses and Opportunistic Infections, Rebecca Denison, a decades-long HIV ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback